About LevitasBio
LevitasBio is a company based in San Francisco (United States) founded in 2017 by Lars Steinmetz, Gozde Durmus, and Utkan Demirci. LevitasBio has raised $73.77 million across 4 funding rounds from investors including Novalis LifeSciences, Pavilion Capital Partners and Decheng Capital. LevitasBio offers products and services including LeviCell EOS, LeviCell 1.0, LeviPrep, LeviSelect, and LeviMetrics. LevitasBio operates in a competitive market with competitors including 10X Genomics, Mission Bio, Cellares, LUMICKS and Biolog, among others.
- Headquarter San Francisco, United States
- Founders Lars Steinmetz, Gozde Durmus, Utkan Demirci
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$73.77 M (USD)
in 4 rounds
-
Latest Funding Round
$11.76 M (USD), Series C
Mar 28, 2024
-
Investors
Novalis LifeSciences
& 2 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of LevitasBio
LevitasBio offers a comprehensive portfolio of products and services, including LeviCell EOS, LeviCell 1.0, LeviPrep, LeviSelect, and LeviMetrics.
Processes samples to improve cell viability and remove debris.
Elevates research by isolating viable cells from low-quality samples.
Handles primary tissues for better dissociation and integrity.
Enriches specific cells without altering their state.
Analyzes levitated samples using AI-based tools.
People of LevitasBio
Unlock access to complete
Unlock access to complete
Funding Insights of LevitasBio
LevitasBio has successfully raised a total of $73.77M across 4 strategic funding rounds. The most recent funding activity was a Series C round of $11.76 million completed in March 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in LevitasBio
LevitasBio has secured backing from 3 investors, including venture fund investors. Prominent investors backing the company include Novalis LifeSciences, Pavilion Capital Partners and Decheng Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investment and advisory services are provided for life sciences.
|
Locked | Locked | Locked | |
|
Growth-stage companies are invested in by this venture capital fund.
|
Locked | Locked | Locked | |
|
Venture capital firm focused on life science and technology sectors
|
Locked | Locked | Locked |
Investor details for LevitasBio
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by LevitasBio
Investment portfolio details for LevitasBio
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - LevitasBio
Detailed financials for LevitasBio
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Levitasbio Comparisons
Peer comparison for LevitasBio
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of LevitasBio
LevitasBio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as 10X Genomics, Mission Bio, Cellares, LUMICKS and Biolog, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Instrument systems for genomic research and sequencing libraries are developed.
|
|
| Locked | Locked | Locked |
Single-cell multi-omics platform is provided for genotypic and phenotypic analysis.
|
|
| Locked | Locked | Locked |
Medical devices for cell-based therapy manufacturing are produced.
|
|
| Locked | Locked | Locked |
Optical tweezers instruments for single-molecule analysis are manufactured.
|
|
| Locked | Locked | Locked |
Cell-based phenotyping technologies and assays are provided for microbial analysis.
|
Detailed competitors of LevitasBio
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Levitasbio
Complete news archive for LevitasBio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about LevitasBio
LevitasBio was founded in 2017.
LevitasBio is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Martin Pieprzyk is the current CEO of LevitasBio.
LevitasBio is a funded company, having raised a total of $73.77M across 4 funding rounds to date.
Founded in 2017 and based in San Francisco, United States, LevitasBio operates in the biotechnology sector. A single-cell imaging and profiling platform, known as the levitation image cytometry platform, is being developed using magnetic levitation technology. This label-free method for cell analysis is intended for applications in therapeutics, diagnostics, and research. The platform enables universal cell profiling without traditional labeling techniques.
LevitasBio's top competitors include 10X Genomics, Mission Bio and Cellares.
LevitasBio offers LeviCell EOS, LeviCell 1.0, LeviPrep, LeviSelect, and LeviMetrics.
LevitasBio has 3 investors. Key investors include Novalis LifeSciences, Pavilion Capital Partners, and Decheng Capital.